Moreover, our correlational analyses of all the cohorts also demonstrated that IP-10 and CXCL9 were positively correlated with BP and HR, which implicated it might be a marker to reflect the therapeutic effect in UPA patients. The gene discussed is CXCL9; the disease is urokinase-type plasminogen activator measurement.